COPENHAGEN (Reuters) -Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a so-called Phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024. “We look forward to initiating a large, comprehensive Phase 2b trial very soon and are now exploring collaboration opportunities with potential partners,” Zealand Pharma […]
Health
Zealand Pharma to start Phase 2b trial for obesity drug candidate in Q4
Audio By Carbonatix
COPENHAGEN (Reuters) -Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a so-called Phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
“We look forward to initiating a large, comprehensive Phase 2b trial very soon and are now exploring collaboration opportunities with potential partners,” Zealand Pharma CEO Adam Steensberg said in a statement.
The company said it expected to initiate the trial with petrelintide in people with overweight or obesity without type 2 diabetes in the fourth quarter and to complete enrolment of patients in the first half of 2025.
It also said it also expected to initiate a Phase 2b trial in the first half of 2025 for patients with overweight or obesity and type 2 diabetes.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)